Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.60 |
| ▸ | DRD1 | P21728 | 7/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpromazine SCHEMBL28086160 | 0.87 | CYP2D6 (0.64) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Promethazine SCHEMBL28086227 | 0.82 | CHRM2 (0.64) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Pyrilamine SCHEMBL8042302 | 0.81 | LMNA (0.65) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Methylpromazine SCHEMBL18994 | 0.77 | CHRM2 (1.00) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Tripelennamine SCHEMBL17970 | 0.77 | CHRM2 (1.00) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Methylpromazine SCHEMBL29354434 | 0.77 | CHRM2 (1.00) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Methylpromazine SCHEMBL18993 | 0.77 | CHRM2 (1.00) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Tripelennamine SCHEMBL29600775 | 0.77 | CHRM2 (1.00) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Tripelennamine SCHEMBL1639009 | 0.76 | CHRM2 (0.72) | CHRM2ADRA2ADRD1KCNH2SLC6A4 | |
| Methylpromazine SCHEMBL2774391 | 0.76 | CHRM2 (0.97) | CHRM2ADRA2ADRD1KCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023102381-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4181928-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | Hoth Therapeutics, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | MENLO THERAPEUTICS INC. (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | BDKRB2, BDKRB1, PBK | HRH1 122/4885CHRM2 563/4885ADRA2A 253/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | HRH1 233/4885CHRM2 289/4885ADRA2A 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.